| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
TLR2
MMG-11 quarterhydrate targets the Toll-like Receptor 2 (TLR2), specifically the TLR2/1 and TLR2/6 heterodimers. By antagonizing TLR2, it blocks the activation of downstream signaling pathways in response to bacterial lipopeptides, which are natural ligands for TLR2. |
|---|---|
| ln Vitro |
MMG-11 does not exhibit cellular toxicity or interfere with signaling that is triggered by TNF, IL-1β, or other TLR agonists. Up to 100 µM, MMG-11 (0.01-100 µM) does not exhibit any cytotoxic effects on peripheral blood mononuclear cells (PBMCs)[1].
MMG-11 quarterhydrate is potent and selective. It inhibits Pam3CSK4-induced hTLR2/1 signaling with an IC₅0 of 1.7 microM and Pam2CSK4-induced hTLR2/6 response with an IC₅0 of 5.7 microM. At up to 100 uM, it shows no cytotoxic effects on peripheral blood mononuclear cells (PBMCs) and does not interfere with signaling triggered by TNF, IL-1beta, or other TLR agonists. |
| ln Vivo |
Specific in vivo activity data for MMG-11 quarterhydrate is not available in the standard literature. As a research antagonist, its in vivo effect would typically be evaluated by measuring the suppression of TLR2-mediated inflammatory responses in animal models of infection or autoimmunity. Specific in vivo PK/PD data are not reported.
|
| Enzyme Assay |
Standard protocols for TLR antagonist assays involve adding varying concentrations of MMG-11 quarterhydrate (e.g., 0.01, 1, 10, 100 uM) to HEK293 cells co-transfected with human TLR2 and a NF-kappaB luciferase reporter. After pre-incubation, cells are stimulated with the TLR2 agonist Pam3CSK4, and luciferase activity is measured to assess inhibition of TLR2 signaling.
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: PBMCs Tested Concentrations: 0.01, 1, 10, 100 µM Incubation Duration: Experimental Results: demonstrated no cytotoxic effects up to 100 µM. Typical protocols for assessing TLR2 antagonism involve seeding human embryonic kidney 293 (HEK293) cells stably expressing TLR2 and NF-kappaB luciferase reporter. Cells are pre-treated with MMG-11 quarterhydrate at escalating concentrations followed by stimulation with TLR2 ligands. After incubation, cell lysis and luminescence measurement quantify TLR2-driven NF-kappaB activation. |
| Animal Protocol |
Standard procedures for testing TLR2 antagonists in vivo involve administering the compound (e.g., by intraperitoneal injection) to wild-type or humanized TLR2 mouse models before or during bacterial lipopeptide challenge or bacterial infection. Endpoints include measuring serum cytokines (TNF-alpha, IL-6), tissue histology, and survival rates.
|
| ADME/Pharmacokinetics |
MMG-11 quarterhydrate is a small molecule with a molecular weight of 310.78. It is soluble in DMSO at ~100 mg/mL (~321.77 mM). For in vivo use, it can be formulated in co-solvent systems like 10% DMSO + 90% (20% SBE-beta-CD in Saline) or 10% DMSO + 90% Corn Oil to achieve a clear solution.
|
| Toxicity/Toxicokinetics |
MMG-11 quarterhydrate is not a drug but a research tool. For related TLR2 antagonist research, compounds of this class are generally well-tolerated at effective doses, though high-dose studies are limited. PBMC cytotoxicity assays show no significant toxicity up to 100 uM, which corresponds to approximately 31 ug/mL.
|
| References | |
| Additional Infomation |
MMG-11 quarterhydrate is a research-grade TLR2 antagonist. It is a valuable tool for studying inflammation, sepsis, and autoimmune diseases where TLR2 signaling plays a key role. It is not intended for therapeutic use and is not part of any approved clinical trial or marketed product for human use. It is a research tool for investigating innate immunity and for developing new anti-inflammatory therapies.
|
| Molecular Formula |
C15H14O7.1/4H2O
|
|---|---|
| Molecular Weight |
310.78
|
| Related CAS # |
MMG-11;313254-94-3
|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~321.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2177 mL | 16.0886 mL | 32.1771 mL | |
| 5 mM | 0.6435 mL | 3.2177 mL | 6.4354 mL | |
| 10 mM | 0.3218 mL | 1.6089 mL | 3.2177 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
